Fidelity Select Portfolios - Medical Technology and Devices Portfolio Receivables

The latest receivables for FSMEX is $2.3M as of September 2023. That compares with $2.2M in the prior-year period — up 3.8% year over year. Investors often review this figure alongside Fidelity Select Portfolios - Medical Technology and Devices Portfolio's historical trend and sector peers before judging valuation or financial health.

Over the past year, FSMEX's receivables moved from $2.2M to $2.3M — a 3.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fidelity Select Portfolios - Medical Technology and Devices Portfolio's operating scale or balance-sheet position.

A receivables figure of $2.3M for FSMEX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting FSMEX's receivables ($2.3M), review year-over-year change from $2.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.